Hybio Pharmaceutical Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
895
- Stock Symbol
-
300199
- Investments
-
5
- Share Price
-
$1.56
- (As of Friday Closing)
Hybio Pharmaceutical General Information
Description
Hybio Pharmaceutical Co Ltd is engaged in manufacturing and sale of peptide products. The company's peptide finished dosage products include digestive system agents, immune modulators, hormone and endocrine modulators, antiviral agents, and hemostatic products. It also provides peptide CRO and CMO services, as well as API products.
Contact Information
Website
www.hybio.com.cnCorporate Office
- Hybio Medicine Park, No.37, Keji C.2nd
- Shenzhen HI-tech Industrial Park
- Shenzhen, 518057
- China
Corporate Office
- Hybio Medicine Park, No.37, Keji C.2nd
- Shenzhen HI-tech Industrial Park
- Shenzhen, 518057
- China
Hybio Pharmaceutical Stock Performance
As of 17-Jan-2025, Hybio Pharmaceutical’s stock price is $1.56. Its current market cap is $1.37B with 883M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.56 | $1.59 | $1.23 - $2.19 | $1.37B | 883M | 44.5M | -$0.06 |
Hybio Pharmaceutical Financials Summary
As of 30-Sep-2024, Hybio Pharmaceutical has a trailing 12-month revenue of $56.4M.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 1,743,659 | 1,921,934 | 2,523,870 | 2,067,673 |
| Revenue | 56,429 | 60,974 | 104,583 | 113,979 |
| EBITDA | (34,817) | (33,261) | (19,235) | 39,443 |
| Net Income | (51,286) | (72,634) | (55,022) | 4,771 |
| Total Assets | 444,522 | 462,319 | 523,420 | 612,854 |
| Total Debt | 263,536 | 283,434 | 260,587 | 280,135 |
Hybio Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Hybio Pharmaceutical Patents
Hybio Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4458844-A1 | Anti-coronavirus polypeptide, and derivatives thereof and application thereof | Pending | 31-Dec-2021 | ||
| US-20240398893-A1 | Anti-coronavirus polypeptide as well as derivative and application thereof | Pending | 31-Dec-2021 | ||
| JP-2024545339-A | Anti-coronavirus polypeptides, their derivatives and uses thereof | Pending | 31-Dec-2021 | ||
| US-11312744-B2 | Method for purifying long chain polypeptide | Active | 30-May-2018 | ||
| US-20210230216-A1 | Method for purifying long chain polypeptide | Active | 30-May-2018 | C07K14/605 |
Hybio Pharmaceutical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Hybio Pharmaceutical Investments & Acquisitions (5)
Hybio Pharmaceutical’s most recent deal was a Early Stage VC with General Healthy for . The deal was made on 12-Oct-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| General Healthy | 12-Oct-2015 | Early Stage VC | Enterprise Systems (Healthcare) | ||
| General Healthy | 12-Oct-2015 | Secondary Transaction - Private | Enterprise Systems (Healthcare) | ||
| Prediktor | 13-Feb-2015 | Corporate | Systems and Information Management | ||
| Prediktor Medical | 03-Feb-2015 | Secondary Transaction - Private | Monitoring Equipment | ||
| ChanGee | 19-Aug-2014 | Merger/Acquisition | Surgical Devices |
Hybio Pharmaceutical ESG
Risk Overview
Risk Rating
Updated September, 20, 2023
39.71 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,104
Rank
Percentile
Pharmaceuticals
Industry
of 851
Rank
Percentile
Pharmaceuticals
Subindustry
of 424
Rank
Percentile
Hybio Pharmaceutical Exits (4)
Hybio Pharmaceutical’s most recent exit was on 12-Oct-2015 from General Healthy. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| General Healthy | 12-Oct-2015 | Completed |
|
||
| General Healthy | 12-Oct-2015 | Completed |
|
||
| Prediktor | 13-Feb-2015 | Completed |
|
||
| ChanGee | 19-Aug-2014 | Merger/Acquisition | Completed |
Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| ChanGee | Tianshui, China | 2005 |
Hybio Pharmaceutical FAQs
-
When was Hybio Pharmaceutical founded?
Hybio Pharmaceutical was founded in 1998.
-
Where is Hybio Pharmaceutical headquartered?
Hybio Pharmaceutical is headquartered in Shenzhen, China.
-
What is the size of Hybio Pharmaceutical?
Hybio Pharmaceutical has 895 total employees.
-
What industry is Hybio Pharmaceutical in?
Hybio Pharmaceutical’s primary industry is Biotechnology.
-
Is Hybio Pharmaceutical a private or public company?
Hybio Pharmaceutical is a Public company.
-
What is Hybio Pharmaceutical’s stock symbol?
The ticker symbol for Hybio Pharmaceutical is 300199.
-
What is the current stock price of Hybio Pharmaceutical?
As of 17-Jan-2025 the stock price of Hybio Pharmaceutical is $1.56.
-
What is the current market cap of Hybio Pharmaceutical?
The current market capitalization of Hybio Pharmaceutical is $1.37B.
-
What is Hybio Pharmaceutical’s current revenue?
The trailing twelve month revenue for Hybio Pharmaceutical is $56.4M.
-
What is Hybio Pharmaceutical’s annual earnings per share (EPS)?
Hybio Pharmaceutical’s EPS for 12 months was -$0.06.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
